CTOs on the Move

Discovery Life Sciences

www.dls.com

 
Discovery Life Sciences, the Biospecimen and Biomarker Specialists™, is a leading provider of highly characterized human biospecimens and cellular starting materials integrated with expert multi-omic analytical services to advance cell and gene therapy and precision medicine programs for cancer, infectious disease, and other complex conditions. Our robust biospecimen and biomarker platform is optimized for speed and large scale capacity. We routinely manage hundreds of studies and expertly test thousands of biospecimens simultaneously as a single vendor - eliminating time consuming and inefficient transfers of biospecimens or data between different vendors. We offer one of the largest recallable donor pools, Research ...
  • Number of Employees: 250-1000
  • Annual Revenue: $50-100 Million
  • www.dls.com
  • 800 Hudson Way Suite 1700
    Huntsville, AL USA 35806
  • Phone: 866.838.2798

Executives

Name Title Contact Details
Daniel McCormick
Vice President, Information Technology Profile
Jerry Franzella
Global Chief Information Officer - CIO Profile

Similar Companies

Anixa Biosciences

Anixa is a publicly-traded biotechnology company developing a number of programs addressing cancer and infectious disease.

Hospria

Hospria is a Lake Forest, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Carbon Sciences, Inc

Carbon Sciences Inc. is developing a breakthrough technology to transform carbon dioxide (CO2) emissions into the basic fuel building blocks required to produce gasoline, diesel fuel, jet fuel and other portable fuels.

Tactical Therapeutics

Tactical Therapeutics is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Aeglea

With its acquisition of Spyre Therapeutics, Aeglea is shifting its disease focus to inflammatory bowel disease (IBD). Spyre combines best-in-class antibody engineering, rational therapeutic combinations, and precision immunology approaches to maximize efficacy, safety, and convenience of treatments for IBD.